Literature DB >> 19500098

Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction.

Tae Young Kim1, Jongmin Park, Bora Oh, Hyun Jung Min, Tae-Sook Jeong, Jae Hoon Lee, Cheolwon Suh, June-Won Cheong, Hyo Jung Kim, Sung-Soo Yoon, Seung Bum Park, Dong Soon Lee.   

Abstract

Bortezomib is a therapeutic proteasome inhibitor with antimyeloma activity and polyphenols are well known compounds that exert antiproliferative effects against tumuors. We attempted to co-treat myeloma cells with bortezomib and polyphenols, anticipating a synergistic effect. However, the anticancer activity of bortezomib was blocked by the polyphenols. The structural features of the polyphenols correlated strikingly with their antagonistic effect; in particular, the presence or absence of a vicinal diol moiety was the key element for effective blockage of the anticancer function of bortezomib. We speculated that the vicinal diols in the polyphenols interact with the boronic acid of bortezomib and convert the active triangular boronic acid of bortezomib to an inactive tetrahedral boronate, thus abolishing the antimyeloma activity of bortezomib. We confirmed this hypothesis by (11)B nuclear magnetic resonance spectroscopy and an in vitro assay on multiple myeloma (MM) cell lines and primary myeloma cells from patients. Based on these findings, restriction of the intake of natural polyphenols in foods or vitamin supplements during bortezomib treatment in MM patients should be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19500098     DOI: 10.1111/j.1365-2141.2009.07752.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols.

Authors:  Stephen J Glynn; Kevin J Gaffney; Marcos A Sainz; Stan G Louie; Nicos A Petasis
Journal:  Org Biomol Chem       Date:  2015-04-07       Impact factor: 3.876

Review 2.  Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.

Authors:  Jae Hoon Lee; Dong Soon Lee; Je Jung Lee; Yoon Hwan Chang; Jong Youl Jin; Deog-Yeon Jo; Soo Mee Bang; Hyo Jung Kim; Jin Seok Kim; Kihyun Kim; Hyeon Seok Eom; Chang Ki Min; Sung Soo Yoon; Sun Hee Kim; Cheolwon Suh; Kyung Sam Cho
Journal:  Int J Hematol       Date:  2010-06-11       Impact factor: 2.490

Review 3.  The chemopreventive and chemotherapeutic potentials of tea polyphenols.

Authors:  Vijay S Thakur; Karishma Gupta; Sanjay Gupta
Journal:  Curr Pharm Biotechnol       Date:  2012-01       Impact factor: 2.837

Review 4.  The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.

Authors:  Di Chen; Q Ping Dou
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

Review 5.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Authors:  D Chen; M Frezza; S Schmitt; J Kanwar; Q P Dou
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

Review 6.  Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Authors:  B C Potts; M X Albitar; K C Anderson; S Baritaki; C Berkers; B Bonavida; J Chandra; D Chauhan; J C Cusack; W Fenical; I M Ghobrial; M Groll; P R Jensen; K S Lam; G K Lloyd; W McBride; D J McConkey; C P Miller; S T C Neuteboom; Y Oki; H Ovaa; F Pajonk; P G Richardson; A M Roccaro; C M Sloss; M A Spear; E Valashi; A Younes; M A Palladino
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

7.  Protective effects of apigenin on altered lipid peroxidation, inflammation, and antioxidant factors in methotrexate-induced hepatotoxicity.

Authors:  Mehdi Goudarzi; Mojtaba Kalantar; Elahe Sadeghi; Mojtaba Haghi Karamallah; Hadi Kalantar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-15       Impact factor: 3.000

Review 8.  New applications of old metal-binding drugs in the treatment of human cancer.

Authors:  Sara M Schmitt; Michael Frezza; Qing Ping Dou
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

9.  Induction of cell cycle arrest and apoptosis by CPUC002 through stabilization of p53 and suppression of STAT3 signaling pathway in multiple myeloma.

Authors:  Yue Zhao; Dongsheng Bai; Jiaying Du; Haochuan Ren; Zhenguo Zhang; Cheng Jiang; Na Lu
Journal:  Cell Biol Toxicol       Date:  2020-10-30       Impact factor: 6.691

Review 10.  Why bortezomib cannot go with 'green'?

Authors:  Li Jia; Feng-Ting Liu
Journal:  Cancer Biol Med       Date:  2013-12       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.